# US 2019/0376119 A1 · Detection assay for protein-polynucleotide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376119 A1
- Document ID: US20190376119A1
- Status: Published application
- Kind: A1
- Application number: 16/434,056
- Filed: 2019-06-06
- Published: 2019-12-12
- Earliest claimed: 2018-06-07
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Mai THAYER; Sara HUMPHREYS
- Web page: https://patentgrep.com/patent/US20190376119A1

## CPC

- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6839: Triple helix formation or other higher order conformations in hybridisation assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods for detecting and quantifying intact protein-polynucleotide conjugate molecules in various sample matrices. In particular, the methods utilize triplex forming oligonucleotides in combination with protein-specific binding partners to respectively detect the polynucleotide and protein components of the conjugate molecules.

## Claims

### Claim 1

A method for detecting protein-polynucleotide conjugate molecules in a sample comprising:
(a) contacting the sample with a triplex forming oligonucleotide (TFO) that is covalently linked to a tag under conditions that allow the TFO to hybridize to the polynucleotide in the conjugate molecule, thereby forming a hybridization mixture;
(b) contacting the hybridization mixture with a surface comprising a capture reagent that specifically binds to the tag covalently linked to the TFO;
(c) contacting the surface with a detection reagent, wherein the detection reagent comprises a detectable label coupled to a binding partner that specifically binds to the protein in the conjugate molecule; and
(d) detecting a signal from the detectable label.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tag is a hapten.

### Claim 3 (depends on 2)

The method of claim 2, wherein the hapten is biotin, digoxigenin, or 2,4-dinitrophenol.

### Claim 4 (depends on 1)

The method of claim 1, wherein the capture reagent is an antibody that specifically binds to the tag.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tag is biotin and the capture reagent is streptavidin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tag is digoxigenin and the capture reagent is an antibody that specifically binds to digoxigenin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the binding partner is an antibody that specifically binds to the protein in the conjugate molecule.

### Claim 8 (depends on 1)

The method of claim 1, wherein the detectable label is a fluorophore, metallic nanoparticle, enzyme, or electrochemiluminescence (ECL) luminophore.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ECL luminophore is a ruthenium complex.

### Claim 10 (depends on 1)

The method of claim 1, wherein the TFO comprises a mixture of locked nucleic acid (LNA) monomers and deoxyribonucleotides.

### Claim 11 (depends on 10)

The method of claim 10, wherein about 30% to about 40% of the nucleotides in the TFO are LNA monomers.

### Claim 12 (depends on 1)

The method of claim 1, wherein the TFO is at least 15 nucleotides in length.

### Claim 13 (depends on 1)

The method of claim 1, wherein the TFO has a sequence that is complementary to the sequence of the polynucleotide in the conjugate molecule over its entire length.

### Claim 14 (depends on 1)

The method of claim 1, wherein the polynucleotide in the conjugate molecule is an siRNA, an shRNA, a miRNA, a pre-miRNA, or an antisense oligonucleotide.

### Claim 15 (depends on 14)

The method of claim 14, wherein the polynucleotide in the conjugate molecule is an siRNA that comprises a sense strand and an antisense strand, and wherein the TFO has a sequence that is complementary to the sequence of the sense strand.

### Claim 16 (depends on 1)

The method of claim 1, wherein the protein in the conjugate molecule is an antibody or antigen-binding fragment thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the protein in the conjugate molecule is an antibody and the binding partner is a target antigen of the antibody, an anti-Fc region antibody, or an anti-idiotypic antibody.

### Claim 18 (depends on 1)

The method of claim 1, wherein the protein in the conjugate molecule is a ligand of a cell-surface receptor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the binding partner is the receptor or a ligand-binding fragment thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the protein-polynucleotide conjugate molecule is an antibody-siRNA conjugate molecule.

### Claim 21 (depends on 1)

The method of claim 1, wherein the sample is contacted with the TFO at a temperature of about 25° C. to about 60° C., about 45° C. to about 55° C., or about 50° C. to about 55° C. to form the hybridization mixture.

### Claim 22 (depends on 1)

The method of claim 1, wherein the sample is serum, plasma, tissue homogenate, drug substance, or drug product.

### Claim 23

A method for detecting protein-polynucleotide conjugate molecules in a sample comprising:
(a) contacting the sample with a TFO that is covalently linked to a tag under conditions that allow the TFO to hybridize to the polynucleotide in the conjugate molecule, thereby forming a hybridization mixture;
(b) contacting the hybridization mixture with a surface comprising a capture reagent that specifically binds to the protein in the conjugate molecule;
(c) contacting the surface with a detection reagent, wherein the detection reagent comprises a detectable label coupled to a binding partner that specifically binds to the tag covalently linked to the TFO; and
(d) detecting a signal from the detectable label.

### Claim 24 (depends on 23)

The method of claim 23, wherein the tag is a hapten.

### Claim 25 (depends on 24)

The method of claim 24, wherein the hapten is biotin, digoxigenin, or 2,4-dinitrophenol.

### Claim 26 (depends on 23)

The method of claim 23, wherein the binding partner is an antibody that specifically binds to the tag.

### Claim 27 (depends on 23)

The method of claim 23, wherein the tag is biotin and the binding partner is streptavidin.

### Claim 28 (depends on 23)

The method of claim 23, wherein the tag is digoxigenin and the binding partner is an antibody that specifically binds to digoxigenin.

### Claim 29 (depends on 23)

The method of claim 23, wherein the detectable label is a fluorophore, metallic nanoparticle, enzyme, or ECL luminophore.

### Claim 30 (depends on 29)

The method of claim 29, wherein the ECL luminophore is a ruthenium complex.

### Claim 31 (depends on 23)

The method of claim 23, wherein the capture reagent is an antibody that specifically binds to the protein in the conjugate molecule.

### Claim 32 (depends on 23)

The method of claim 23, wherein the TFO comprises a mixture of locked nucleic acid (LNA) monomers and deoxyribonucleotides.

### Claim 33 (depends on 32)

The method of claim 32, wherein about 30% to about 40% of the nucleotides in the TFO are LNA monomers.

### Claim 34 (depends on 23)

The method of claim 23, wherein the TFO is at least 15 nucleotides in length.

### Claim 35 (depends on 23)

The method of claim 23, wherein the TFO has a sequence that is complementary to the sequence of the polynucleotide in the conjugate molecule over its entire length.

### Claim 36 (depends on 23)

The method of claim 23, wherein the sample is contacted with the TFO at a temperature of about 25° C. to about 60° C., about 45° C. to about 55° C., or about 50° C. to about 55° C. to form the hybridization mixture.

### Claim 37 (depends on 23)

The method of claim 23, wherein the polynucleotide in the conjugate molecule is an siRNA, an shRNA, a miRNA, a pre-miRNA, or an antisense oligonucleotide.

### Claim 38 (depends on 37)

The method of claim 37, wherein the polynucleotide in the conjugate molecule is an siRNA that comprises a sense strand and an antisense strand, and wherein the TFO has a sequence that is complementary to the sequence of the sense strand.

### Claim 39 (depends on 23)

The method of claim 23, wherein the protein in the conjugate molecule is an antibody or antigen-binding fragment thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein the protein in the conjugate molecule is an antibody and the capture reagent is a target antigen of the antibody, an anti-Fc region antibody, an anti-idiotypic antibody, protein A, or protein G.

### Claim 41 (depends on 23)

The method of claim 23, wherein the protein in the conjugate molecule is a ligand of a cell-surface receptor.

### Claim 42 (depends on 41)

The method of claim 41, wherein the capture reagent is the receptor or a ligand-binding fragment thereof.

### Claim 43 (depends on 23)

The method of claim 23, wherein the protein-polynucleotide conjugate molecule is an antibody-siRNA conjugate molecule.

### Claim 44 (depends on 23)

The method of claim 23, wherein the sample is serum, plasma, tissue homogenate, drug substance, or drug product.
